Table I:

Substrate Specificities of Victim Drugs and Inhibitory Potential of Perpetrator Drugs for Metabolic Enzymes and Xenobiotic Transporters from Investigated Oral Drug-Drug Interactions

Victim Drug	Dose	BDDCS Class	Substrate Specificity	Perpetrator Drug	Dose	BDDCS Class	Inhibitory Specificity	Reference
Rosuvastatin (Single Dose)	20 mg PO	3	BCRP OATP1B1 OATP1B3	Rifampin (Single Dose)	600 mg IV infusion	2	BCRP OATP1B1 OATP1B3 CYP3A	(20,21)
Talinolol (Multiple Dose)	100 mg PO 7 Days	3	P-gp	Rifampin (Multiple Dose)	600 mg PO q.d. 9 Days	2	(Inducer) CYP3A CYP2C9 P-gp	(22,54)
Triazolam (Single Dose)	0.25 mg PO	1	CYP3A	Fluconazole (Multiple Dose)	100 mg PO q.d. 4 Days	3	CYP3A CYP2C19 CYP2C9	(20,23)
Omeprazole (Multiple Dose)	40 mg PO 6 Days	1	CYP2C19 CYP3A (minor)	Clarithromycin (Multiple Dose)	500 mg PO t.i.d 5.33 Days	3	CYP3A CYP2C19 P-gp	(20,24)
Apixaban (Single Dose)	10 mg PO	1	CYP3A P-gp	Rifampin (Multiple Dose)	600 mg PO q.d. 11 Days	2	(Inducer) CYP3A P-gp	(25,54)

Intestinally expressed enzyme and transporters are highlighted in bold

Abbreviations: BCRP, Breast Cancer Resistance Protein; BDDCS, Biopharmaceutics Drug Disposition Classification System; CYP, Cytochrome P450; IV, Intravenous; OATP, Organic Anion-Transporting Protein; P-gp, P-glycoprotein